IMMUNOTECH LABORATORIES, INC. Inactive Instrument
Immunotech Laboratories, Inc. Stock Other OTC
Equities
IMMB
US45254F2039
Biotechnology & Medical Research
Financials (USD)
| Sales * | - | Sales 1 * | - | Capitalization | 57.5K |
|---|---|---|---|---|---|
| Net income * | - | Net income 1 * | - | EV / Sales * | - |
| Net cash position * | - | Net cash position 1 * | - | EV / Sales 1 * | - |
| P/E ratio * |
-
| P/E ratio 1 * |
-
| Employees | - |
| Yield * |
-
| Yield 1 * |
-
| Free-Float | 10.1% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Harry Zhabilov
CHM | Chairman | 57 | 07-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Harry Zhabilov
CHM | Chairman | 57 | 07-11-30 |
| Director/Board Member | 59 | 13-02-03 |
Immunotech Laboratories, Inc. (Immunotech) is a drug development company that focuses on research and development in the biotechnology field. The Company is also focused on the commercialization of its proprietary proteins known as Irreversible Pepsin Fraction (IPF) ITV-1 for the treatment of debilitating infectious diseases, such as human immunodeficiency virus (HIV) and Hepatitis Type C.
| 1st Jan change | Capi. | |
|---|---|---|
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
